Financials
Financial year 2025
Fabbro BioPharm Consulting from Anzegem, company number BE0739732886, closed financial year 2025 with a result of € 113,359 after tax. For that financial year Fabbro BioPharm Consulting recorded a gross margin of € 158,737 and equity of € 732,063. Compared with financial year 2024, the result moved from € 193,654 to € 113,359. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on April 28, 2026.
€ 732,063
▲ 18% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 113,359
▼ 41% vs 2024
Profit after tax over the fiscal year.
€ 713,856
▲ 67% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 727,063.
People and assets in 2025
€ 952
▼ 70% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 2,420
▲ € 2,103 vs 2024
Loans from banks and other lenders, long and short.
€ 9,410
▲ 22% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 2,176
▼ 95% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 64,132 | € 7,210 | € 282,846 | € 158,737 | ▼ 44% |
| Profit after taxes | € 43,796 | € 3,182 | € 193,654 | € 113,359 | ▼ 41% |
| Equity | € 421,867 | € 425,049 | € 618,704 | € 732,063 | ▲ 18% |
| Total debts | € 3,838 | € 17,816 | € 64,358 | € 25,835 | ▼ 60% |
| Cash | € 417,526 | € 404,493 | € 428,286 | € 713,856 | ▲ 67% |
| Retained profit | € 416,867 | € 420,049 | € 613,704 | € 727,063 | ▲ 18% |
| Bank debt | € 0 | € 360 | € 317 | € 2,420 | ▲ € 2,103 |
| Balance sheet total | € 425,705 | € 442,865 | € 683,062 | € 757,898 | ▲ 11% |
Key figures of Fabbro BioPharm Consulting, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 April 2027.
What happened to Fabbro BioPharm Consulting?
What happened at Fabbro BioPharm Consulting in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 113,359 (▼ 41% vs 2024). Source: NBB ↗
- New establishment in Anzegem. KBO
- Start of the company according to the CBE. KBO
- Frank Marie Fabbro became a director. NBB
In short
From € 43,796 profit in 2022 to € 113,359 profit in 2025.
Paid € 151,218 in corporate taxes since 2022.
Best year ever: 2024, with € 193,654 profit.
A new publication or filing at Fabbro BioPharm Consulting? We notify you, reason included.
Follow Fabbro BioPharm ConsultingDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Fabbro BioPharm Consulting is Frank Marie Fabbro.
Directors
According to the 2025 annual accounts
Frank Marie Fabbro
Director
since 2019
Establishments
Establishment units
Physical locations of this company
Deerlijkstraat 27
8570 Anzegem
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0739.732.886
- VAT number
- BE 0739.732.886
- Registered office
- Deerlijkstraat 27, 8570 Anzegem
- Names & denominations
- Fabbro BioPharm Consulting
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 18 December 2019
- Peppol
- Active · Active since 21 Dec 2025
- Activities · NACE
Activiteiten van adviesbureaus op het gebied van public relations en communicatie
Adviesbureaus op het gebied van public relations en communicatie